Trial Profile
Retrospective Study Based on Somatic Mutations, Genetic Polymorphisms and Metabolomics Related to Individual Variations of Drug Effect and Adverse Drug Reaction of EGFR-TKIs,Gefitinib and Erlotinib in Non-small Cell Lung Cancer Treatment
Status:
Recruiting
Phase of Trial:
Phase IV
Latest Information Update: 14 Apr 2023
Price :
$35
*
At a glance
- Drugs Erlotinib (Primary) ; Gefitinib (Primary)
- Indications Adenocarcinoma; Non-small cell lung cancer
- Focus Pharmacogenomic; Therapeutic Use
- 10 Apr 2023 Planned primary completion date changed from 1 Oct 2022 to 1 Oct 2025.
- 10 Apr 2023 Planned End Date changed from 1 Dec 2025 to 1 Dec 2026.
- 25 Oct 2022 Planned End Date changed from 1 Dec 2022 to 1 Dec 2025.